Jump to content

Pharmacophore: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
m →History: Added 1 doi to a journal cite using AWB (10193)
Fix numbered list according to guidelines (http://en.wikipedia.org/wiki/Help:List) so that the counter is not reset with each item.
Line 12: Line 12:
The process for developing a pharmacophore model generally involves the following steps:
The process for developing a pharmacophore model generally involves the following steps:


⚫
#'''Select a set of molecules'''<p>Select a set of molecules that will be used for developing the pharmacophore model. As a pharmacophore model should be able to discriminate between molecules with and without bioactivity, the set of molecules should include both active and inactive compounds.</p>
#'''Select a set of molecules'''
⚫
#'''Conformational analysis'''<p>Perform [[conformational analysis]] of the individual molecules and select a presumed ''bioactive conformation'' for each. For a pharmacophore model to be valid, the proposed bioactive conformation of a molecule should be a low-energy conformation.</p>

⚫
#'''Molecular superimposition'''<p>Superimpose ("fit") the low-energy conformations of the molecules. Similar functional groups common to all molecules in the set might be fitted (''e.g.'', phenyl rings or carboxylic acid groups).</p>
⚫
Select a set of molecules that will be used for developing the pharmacophore model. As a pharmacophore model should be able to discriminate between molecules with and without bioactivity, the set of molecules should include both active and inactive compounds.
⚫
#'''Abstract description'''<p>Transform the superimposed molecules into an abstract representation. For example, superimposed phenyl rings might be referred to more conceptually as an 'aromatic ring' pharmacophore element. Likewise, hydroxy groups could be designated as a '[[hydrogen-bond]] donor/acceptor' pharmacophore element.</p>

⚫
#'''Validation'''<p>A pharmacophore model is basically a ''hypothesis'' accounting for the observed biological activities of a set of molecules. The model is only valid insofar as it is able to account for differences in biological activity of a range of molecules.</p>
#'''Conformational analysis'''

⚫
Perform [[conformational analysis]] of the individual molecules and select a presumed ''bioactive conformation'' for each. For a pharmacophore model to be valid, the proposed bioactive conformation of a molecule should be a low-energy conformation.

#'''Molecular superimposition'''

⚫
Superimpose ("fit") the low-energy conformations of the molecules. Similar functional groups common to all molecules in the set might be fitted (''e.g.'', phenyl rings or carboxylic acid groups).

#'''Abstract description'''

⚫
Transform the superimposed molecules into an abstract representation. For example, superimposed phenyl rings might be referred to more conceptually as an 'aromatic ring' pharmacophore element. Likewise, hydroxy groups could be designated as a '[[hydrogen-bond]] donor/acceptor' pharmacophore element.

#'''Validation'''

⚫
A pharmacophore model is basically a ''hypothesis'' accounting for the observed biological activities of a set of molecules. The model is only valid insofar as it is able to account for differences in biological activity of a range of molecules.


<br />As the biological activities of new molecules become available, the pharmacophore model can be updated to further refine it.
<br />As the biological activities of new molecules become available, the pharmacophore model can be updated to further refine it.

Revision as of 03:23, 29 July 2014

An example of a pharmacophore model.

A pharmacophore is an abstract description of molecular features which are necessary for molecular recognition of a ligand by a biological macromolecule. The IUPAC defines a pharmacophore to be "an ensemble of steric and electronic features that is necessary to ensure the optimal supramolecular interactions with a specific biological target and to trigger (or block) its biological response".[1] A pharmacophore model explains how structurally diverse ligands can bind to a common receptor site. Furthermore pharmacophore models can be used to identify through denovo design or virtual screening novel ligands that will bind to the same receptor.

Features

Superposition of the chemical structures of a benzodiazepine and nonbenzodiazepine ligand and their interactions with binding sites within the receptor.
An example of a pharmacophore model of the benzodiazepine binding site on the GABAA receptor.[2] White sticks represent the carbon atoms of the benzodiazepine diazepam, while green represents carbon atoms of the nonbenzodiazepine CGS-9896. Red and blue sticks are oxygen and nitrogen atoms that are present in both structures. The red spheres labeled H1 and H2/A3 are, respectively, hydrogen bond donating and accepting sites in the receptor, while L1, L2, and L3 denote lipophilic binding sites.

Typical pharmacophore features include hydrophobic centroids, aromatic rings, hydrogen bond acceptors or donor, cations, and anions. These pharmacophoric points may be located on the ligand itself or may be projected points presumed to be located in the receptor.

The features need to match different chemical groups with similar properties, in order to identify novel ligands. Ligand-receptor interactions are typically “polar positive”, “polar negative” or “hydrophobic”. A well-defined pharmacophore model includes both hydrophobic volumes and hydrogen bond vectors.

Process for pharmacophore model development

The process for developing a pharmacophore model generally involves the following steps:

  1. Select a set of molecules

    Select a set of molecules that will be used for developing the pharmacophore model. As a pharmacophore model should be able to discriminate between molecules with and without bioactivity, the set of molecules should include both active and inactive compounds.

  2. Conformational analysis

    Perform conformational analysis of the individual molecules and select a presumed bioactive conformation for each. For a pharmacophore model to be valid, the proposed bioactive conformation of a molecule should be a low-energy conformation.

  3. Molecular superimposition

    Superimpose ("fit") the low-energy conformations of the molecules. Similar functional groups common to all molecules in the set might be fitted (e.g., phenyl rings or carboxylic acid groups).

  4. Abstract description

    Transform the superimposed molecules into an abstract representation. For example, superimposed phenyl rings might be referred to more conceptually as an 'aromatic ring' pharmacophore element. Likewise, hydroxy groups could be designated as a 'hydrogen-bond donor/acceptor' pharmacophore element.

  5. Validation

    A pharmacophore model is basically a hypothesis accounting for the observed biological activities of a set of molecules. The model is only valid insofar as it is able to account for differences in biological activity of a range of molecules.


As the biological activities of new molecules become available, the pharmacophore model can be updated to further refine it.

Applications

In modern computational chemistry, pharmacophores are used to define the essential features of one or more molecules with the same biological activity. A database of diverse chemical compounds can then be searched for more molecules which share the same features arranged in the same relative orientation.

Pharmacophores are also used as the starting point for developing 3D-QSAR models.

History

Historically, pharmacophores were established by Lemont Kier, who first mentions the concept in 1967[3] and uses the term in a publication in 1971.[4]

The development of the concept is often erroneously accredited to Paul Ehrlich. However neither the alleged source[5] nor any of his other works mention the term "pharmacophore" or make use of the concept.[6]

See also

References

  1. ^ Wermuth CG, Ganellin CR, Lindberg P, Mitscher LA (1998). "Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998)". Pure and Applied Chemistry. 70 (5): 1129–1143. doi:10.1351/pac199870051129.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  2. ^ Madsen U, Bräuner-Osborne H, Greenwood JR, Johansen TN, Krogsgaard-Larsen P, Liljefors T, Nielsen M, Frølund B (2005). "GABA and Glutamate receptor ligands and their therapeutic potential in CNS disorders". In Gad SC (ed.). Drug Discovery Handbook. Hoboken, N.J: Wiley-Interscience/J. Wiley. pp. 797–907. ISBN 0-471-21384-5.{{cite book}}: CS1 maint: multiple names: authors list (link)
  3. ^ Kier LB (September 1967). "Molecular orbital calculation of preferred conformations of acetylcholine, muscarine, and muscarone". Mol. Pharmacol. 3 (5): 487–94. PMID 6052710.
  4. ^ Kier LB (1971). Molecular orbital theory in drug research. Boston: Academic Press. pp. 164–169. ISBN 0-12-406550-3.
  5. ^ Ehrlich P (1909). "Über den jetzigen Stand der Chemotherapie". Ber. Dtsch. Chem. Ges. 42: 17–47. doi:10.1002/cber.19090420105.
  6. ^ "Monty Kier and the Origin of the Pharmacophore Concept" (PDF). Internet Electronic Journal of Molecular Design. 6: 271–279. 2007. {{cite journal}}: Unknown parameter |authors= ignored (help)

Further reading

  • Güner OF, ed. (1999). Pharmacophore perception, development, and use in drug design. LaJolla, CA: International University Line. ISBN 0-9636817-6-1.
  • Langer T, Hoffmann RD (2006). Pharmacophores and pharmacophore searches. Weinheim: WILEY-VCH. ISBN 3-527-31250-1.

The following computer software packages enable the user to model the pharmacophore using a variety of computational chemistry methods:

Retrieved from "https://en.wikipedia.org/w/index.php?title=Pharmacophore&oldid=618913253"